First National Bank of Omaha raised its stake in Novartis AG (NYSE:NVS) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 100,464 shares of the company’s stock after buying an additional 774 shares during the quarter. First National Bank of Omaha’s holdings in Novartis were worth $8,435,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Cetera Investment Advisers bought a new stake in shares of Novartis in the second quarter worth $241,000. Bartlett & Co. LLC increased its stake in Novartis by 1.6% during the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after buying an additional 7,249 shares in the last quarter. Capital Bank & Trust Co increased its stake in Novartis by 5.5% during the 3rd quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after buying an additional 7,201 shares in the last quarter. Atlantic Trust Group LLC increased its stake in Novartis by 54.2% during the 3rd quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after buying an additional 25,452 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new stake in Novartis during the 3rd quarter worth approximately $1,245,000. 11.06% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have commented on NVS. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, October 24th. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Leerink Swann upped their price target on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $85.32.
Novartis AG (NYSE NVS) traded up $1.37 during mid-day trading on Wednesday, hitting $84.97. The stock had a trading volume of 703,049 shares, compared to its average volume of 1,713,054. Novartis AG has a 1-year low of $72.67 and a 1-year high of $94.19. The stock has a market capitalization of $194,689.48, a price-to-earnings ratio of 26.09, a PEG ratio of 1.95 and a beta of 0.73. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31.
Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The firm had revenue of $12.92 billion for the quarter, compared to analysts’ expectations of $12.65 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. equities research analysts forecast that Novartis AG will post 5.36 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “First National Bank of Omaha Boosts Stake in Novartis AG (NYSE:NVS)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/first-national-bank-of-omaha-raises-position-in-novartis-ag-nvs.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.